Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-26T23:55:13.013Z Has data issue: false hasContentIssue false
  • English
  • Français

An effective approach to decrease antipsychotic and benzodiazepine use in nursing homes: the RedUSe project

Published online by Cambridge University Press:  09 October 2009

Juanita Westbury ,
Shane Jackson ,
Peter Gee  and
Gregory Peterson
Juanita Westbury*
Affiliation:
Unit for Medication Outcomes, Research and Education (UMORE), School of Pharmacy, University of Tasmania, Hobart, Tasmania, Australia
Shane Jackson
Affiliation:
Unit for Medication Outcomes, Research and Education (UMORE), School of Pharmacy, University of Tasmania, Hobart, Tasmania, Australia
Peter Gee
Affiliation:
Unit for Medication Outcomes, Research and Education (UMORE), School of Pharmacy, University of Tasmania, Hobart, Tasmania, Australia
Gregory Peterson
Affiliation:
Unit for Medication Outcomes, Research and Education (UMORE), School of Pharmacy, University of Tasmania, Hobart, Tasmania, Australia
*
Correspondence should be addressed to: Juanita Westbury MSc, BPharm, University of Tasmania, Unit of Medication Outcomes Research and Education, School of Pharmacy, Private Bag 83, Hobart, Tasmania 7001. Phone: +61 3 6226 1966; Fax: +61 3 6226 7627. Email: [email protected].
Get access Rights & Permissions [Opens in a new window]

Abstract

Background: This study evaluated a multi-faceted, interdisciplinary intervention to reduce the use of benzodiazepines and antipsychotics in nursing homes – the “RedUSe” (Reducing Use of Sedatives) project.

Methods: The RedUSe project was a controlled trial conducted in 25 nursing homes in Tasmania, with 13 intervention and 12 control homes. A series of pharmacist-led strategies were provided to intervention homes including two medication audit and feedback cycles, educational sessions for staff and an interdisciplinary sedative review. Data on psychotropic drug use at each nursing home were collected utilizing a customized computer program at baseline, 12 and 26 weeks. The RedUSe project was registered as a controlled trial at the Australian New Zealand Clinical Trials Registry, registration number: ACTRN12608000221358.

Results: For each measure, an average of 1591 residents were audited. Over the six-month trial, there was a significant reduction in the percentage of intervention home residents regularly taking benzodiazepines (31.8% to 26.9%, p < 0.005) and antipsychotics (20.3% to 18.6%, p < 0.05), whereas control home psychotropic use did not alter significantly. For residents taking benzodiazepines and antipsychotics at baseline, there were significantly more dose reductions/cessations in intervention homes than in control homes (benzodiazepines: 39.6% vs. 17.6%, p < 0.0001; antipsychotics: 36.9% vs. 20.9%, p < 0.01).

Conclusions: RedUSe led to a significant reduction in the proportion of residents in nursing homes taking benzodiazepines and antipsychotics, and a significant increase in the number of dose reductions of these agents. Our findings suggest that a multi-faceted program, coordinated through a community pharmacy, can offer an effective approach in reducing psychotropic use in nursing homes.

Keywords

antipsychoticbenzodiazepinenursing homesintervention trialpsychotropic
Type
2009 IPA JUNIOR RESEARCH AWARDS – THIRD-PRIZE WINNER
Information
International Psychogeriatrics , Volume 22 , Issue 1 , February 2010 , pp. 26 - 36
Copyright
Copyright © International Psychogeriatric Association 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association (2007). American Psychiatric Association. Practice Guideline for the Treatment of Patients with Alzheimer's Disease and Other Dementias. 2nd edn. Available at: http://www.psych.org (last accessed 11 November 2008).Google Scholar
Australian Pharmaceutical Advisory Council (2002). Guidelines for Medication Management in Residential Aged Care Facilities. 3rd edn. Canberra: Commonwealth of Australia.Google Scholar
Australian Senate (1995). Psychotherapeutic Medication in Australia: Report of the Senate Community Affairs References Committee. Canberra: Australian Government Printing Service.Google Scholar
Avorn, J. et al. (1992). A randomised trial of a program to reduce the use of psychoactive drugs in nursing homes. New England Journal of Medicine, 327, 168–173CrossRefGoogle ScholarPubMed
Ballard, C., Waite, J. and Birks, J. (2006). Atypical antipyschotics for aggression and psychosis in Alzheimer's disease. Cochrane Database of Systematic Reviews, 1, CD003476.Google Scholar
Ballard, C. et al. (2009). The dementia antipsychotic withdrawal trial (DART-AD): long -term follow-up of a randomised placebo-controlled trial. Lancet Neurology, 8, 151–157.Google Scholar
Conn, D. and Madan, R. (2006). Use of sleep-promoting medications in nursing home residents. Drugs and Aging, 23, 271–287.CrossRefGoogle ScholarPubMed
Crotty, M. et al. (2004). An outreach intervention to implement evidence based practice in residential care: a randomised controlled trial. BMC Health Services Research, 4, 6.CrossRefGoogle Scholar
Department of Health and Ageing (2007). Aged Care Homes: Residential Medication Management Review. Available at http://www.guild.org.au/uploadedfiles/Medication_Management_Reviews/Residential_Medication_Management_Reviews/RMMR-Current_model.pdf.Google Scholar
Draper, B. et al. (2001). Use of psychotropics in Sydney nursing homes: associations with depression, psychosis, and behavioral disturbances. International Psychogeriatrics, 13, 107–120.Google Scholar
Fonad, E., Robins Wahlin, T., Winblad, R., Emami, A. and Sandmark, H. (2008). Falls and fall risk among nursing home residents. Journal of Clinical Nursing, 17, 126–134.CrossRefGoogle ScholarPubMed
International Psychogeriatric Association (2004). Primary Care Physicians Guide to BPSD. Available at www.ipa-online.org/ipaonlinev3/ipaprograms/bpsdarchives/bpsdrev/pcg.pdf (last accessed 8 September 2009).Google Scholar
Madhusoodanan, S. and Bogunovic, O. (2004). Safety of benzodiazepines in the geriatric population. Expert Opinion Patient Safety, 3, 485–493.CrossRefGoogle ScholarPubMed
Monette, J. et al. (2008). Effect of an interdisciplinary educational program on antipsychotic prescribing among nursing home residents with dementia. International Journal of Geriatric Psychiatry, 23, 574–579.CrossRefGoogle ScholarPubMed
Nishtala, P., McLachlan, A., Bell, J. and Chen, T. (2008). Psychotropic prescribing in long-term care facilities: impact of medication reviews and educational interventions. American Journal of Geriatric Psychiatry, 16, 621–632.CrossRefGoogle ScholarPubMed
Ray, W., Blazer, D., Schaffner, W. and Federspiel, C. (1987). Reducing antipsychotic drug prescribing for nursing home patients: a controlled trial of the effect of an educational visit. American Journal of Public Health, 77, 1448–1450.CrossRefGoogle ScholarPubMed
Roberts, M. et al. (2001). Outcomes of a randomised controlled trial of a clinical pharmacy intervention in 52 nursing homes. British Journal of Clinical Pharmacology, 51, 257–265.CrossRefGoogle ScholarPubMed
Royal Australian College of General Practitioners (2005). Medical care of older persons in residential aged care facilities. Silver Book National Taskforce, 4th edn. Available at http://www.racgp.org.au/silverbookonline (last accessed 8 September 2009).Google Scholar
Royal Australian College of General Practitioners (2000). Guidelines for the Rational Use of Benzodiazepines. Available at http://www.racgp.org.au/guidelines/benzodiazepines (last accessed 8 September 2009).Google Scholar
Schmidt, I., Claesson, C., Westerholm, B., Nilsson, L. and Svarstad, B. (1998). The impact of regular multidisciplinary team interventions on psychotropic prescribing in Swedish nursing homes. Journal of the American Geriatrics Society, 46, 77–82.CrossRefGoogle ScholarPubMed
Schneider, L., Dagerman, M. and Insel, P. (2006). Efficacy and Adverse effects of atypical Antipsychotics for dementia: Meta-analysis of randomised, placebo-controlled trials. American Journal of Geriatric Psychiatry, 14, 191–210.Google Scholar
Snowdon, J., Day, S. and Baker, W. (2005). Current use of psychotropic medication in nursing homes. International Psychogeriatrics, 17, 1–10.Google Scholar
Westbury, J., Jackson, S. and Peterson, G. (2009). Psycholeptic use in Tasmanian aged care homes. International Journal of Clinical Pharmacy and Therapeutics. In press.Google Scholar
Woodward, M. (2006). Hypnosedatives and the elderly – are we doing enough to reduce risk and improve outcomes? Journal of Pharmacy Practice and Research, 36, 5.Google Scholar